Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

[1]  N. Lee,et al.  A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. , 2020, International journal of radiation oncology, biology, physics.

[2]  I. Treilleux,et al.  Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial , 2019, Annals of Oncology.

[3]  E. Vokes,et al.  A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer , 2019, Head & neck.

[4]  Qiaojun He,et al.  Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors , 2019, Expert opinion on drug metabolism & toxicology.

[5]  A. Markham.  Alpelisib: First Global Approval , 2019, Drugs.

[6]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[7]  B. Rotblat,et al.  Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. , 2019, JCI insight.

[8]  J. Mayerle,et al.  The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma , 2019, Cell Death Discovery.

[9]  E. Hirsch,et al.  Class II PI3K Functions in Cell Biology and Disease. , 2019, Trends in cell biology.

[10]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[11]  A. Dechaphunkul,et al.  Frequency of PIK3CA mutations in head and neck squamous cell carcinoma (HNSCC) in southern Thailand. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T. Taxter,et al.  Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer , 2018, Oncology letters.

[13]  K. Fung,et al.  ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. , 2018, Oral oncology.

[14]  B. Keam,et al.  TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[15]  B. Wollenberg,et al.  Inhibition of GSK3α/β impairs the progression of HNSCC , 2018, Oncotarget.

[16]  J. Baselga,et al.  Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer , 2018, Cancer Chemotherapy and Pharmacology.

[17]  R. Mehra,et al.  Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC) , 2018, Cancers of the Head & Neck.

[18]  Sourav Bandyopadhyay,et al.  Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. , 2018, Cancer research.

[19]  Sindeval José da Silva,et al.  Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients , 2018, Virchows Archiv.

[20]  G. Wilson,et al.  Dual blockade of PI3K and MEK in combination with radiation in head and neck cancer , 2018, Clinical and translational radiation oncology.

[21]  Yu Zhang,et al.  PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. , 2018, Future oncology.

[22]  A. Rana,et al.  Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion , 2018, Cellular Oncology.

[23]  S. Libutti,et al.  Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors , 2017, The oncologist.

[24]  R. Mancinelli,et al.  Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases , 2017, Oxidative medicine and cellular longevity.

[25]  A. Markham.  Copanlisib: First Global Approval , 2017, Drugs.

[26]  Xiaoshan Feng,et al.  Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity , 2017, Molecular carcinogenesis.

[27]  F. Janku.  Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. , 2017, Cancer treatment reviews.

[28]  N. Leslie,et al.  GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. , 2017, Advances in biological regulation.

[29]  David M. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[30]  A. Drilon,et al.  A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel , 2017, Investigational New Drugs.

[31]  Sung-Bae Kim,et al.  Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. , 2017, The Lancet. Oncology.

[32]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[33]  F. Toledo,et al.  First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  R. Motzer,et al.  A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma , 2016, The oncologist.

[35]  Wei Hu,et al.  UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway , 2016, Oncotarget.

[36]  Obi L. Griffith,et al.  A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[37]  S. Jane,et al.  Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma. , 2015, Journal of the National Cancer Institute.

[38]  Alissa M. Weaver,et al.  Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. , 2015, JAMA otolaryngology-- head & neck surgery.

[39]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[40]  C. Rudin,et al.  A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. , 2015, Oral oncology.

[41]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[42]  T. Libermann,et al.  Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma , 2015, Molecular biology of the cell.

[43]  G. Shapiro,et al.  First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer , 2015, Clinical Cancer Research.

[44]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[45]  D. Durden,et al.  Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma , 2015, Cancer Chemotherapy and Pharmacology.

[46]  James B. Mitchell,et al.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384 , 2014, Clinical Cancer Research.

[47]  E. Hirsch,et al.  PI3K/AKT signaling pathway and cancer: an updated review , 2014, Annals of medicine.

[48]  A. Jimeno,et al.  A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck , 2014, Investigational New Drugs.

[49]  R. Bianco,et al.  The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models , 2014, British Journal of Cancer.

[50]  D. Erdmann,et al.  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.

[51]  M. Robson,et al.  Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors , 2014, Cancer science.

[52]  A. Haegebarth,et al.  BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models , 2013, Molecular Cancer Therapeutics.

[53]  T. Bush,et al.  AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models , 2013, Molecular Cancer Therapeutics.

[54]  Simion I. Chiosea,et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.

[55]  K. Fung,et al.  High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. , 2013, JAMA otolaryngology-- head & neck surgery.

[56]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[57]  B. Hemmings,et al.  PKB/Akt-dependent regulation of cell motility. , 2013, Journal of the National Cancer Institute.

[58]  Kelvin K. W. Chan,et al.  A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  D. V. Von Hoff,et al.  Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. , 2012, European journal of cancer.

[60]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[61]  R. Schwartz,et al.  Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function , 2012, Nature Medicine.

[62]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[63]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[64]  J. Lehár,et al.  Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel , 2012 .

[65]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[66]  B. Hemmings,et al.  PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis , 2012, Expert Reviews in Molecular Medicine.

[67]  W. Sellers,et al.  Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.

[68]  A. Maity,et al.  Molecular Neuroscience Review Article , 2011 .

[69]  W. Yung,et al.  Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells , 2011, Clinical Cancer Research.

[70]  C. Sutherland.  What Are the bona fide GSK3 Substrates? , 2011, International journal of Alzheimer's disease.

[71]  R. Castro,et al.  Epigenetic modifications: basic mechanisms and role in cardiovascular disease. , 2011, Circulation.

[72]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[73]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[74]  D. Voskas,et al.  Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling? , 2010, F1000 biology reports.

[75]  B. Miao,et al.  Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains , 2010, Proceedings of the National Academy of Sciences.

[76]  J. Asara,et al.  Protein Tyrosine Kinase 6 Directly Phosphorylates AKT and Promotes AKT Activation in Response to Epidermal Growth Factor , 2010, Molecular and Cellular Biology.

[77]  Rajakishore Mishra.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer , 2010, Molecular Cancer.

[78]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[79]  G. Shapiro,et al.  Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer , 2010, Current oncology reports.

[80]  C. Kahn,et al.  Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. , 2010, Cell metabolism.

[81]  Judy Lucas,et al.  Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. , 2010, Journal of medicinal chemistry.

[82]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[83]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[84]  A. Forastiere,et al.  Head and neck cancer: changing epidemiology, diagnosis, and treatment. , 2008, Mayo Clinic proceedings.

[85]  J. Backer.  The regulation and function of Class III PI3Ks: novel roles for Vps34. , 2008, The Biochemical journal.

[86]  J. Engelman,et al.  PI3K Charges Ahead , 2007, Science.

[87]  Yuval Inbar,et al.  Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.

[88]  J. Inazawa,et al.  PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma , 2006, Cancer science.

[89]  L. Cantley,et al.  Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. , 2006, Cell metabolism.

[90]  Spiros Manolidis,et al.  PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma , 2006, Clinical Cancer Research.

[91]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[92]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[93]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[94]  K. Inoki,et al.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.

[95]  J. McCubrey,et al.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy , 2003, Leukemia.

[96]  J. Woodgett,et al.  Multiple Phosphoinositide 3-Kinase-Dependent Steps in Activation of Protein Kinase B , 2002, Molecular and Cellular Biology.

[97]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[98]  P. Shaw,et al.  Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain , 2002, Journal of Chemical Neuroanatomy.

[99]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[100]  M. Waterfield,et al.  Insulin Activates the α Isoform of Class II Phosphoinositide 3-Kinase* , 1999, The Journal of Biological Chemistry.

[101]  E. Querfurth,et al.  Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. , 1996, The EMBO journal.

[102]  A. McMahon,et al.  Wnt genes and vertebrate development. , 1994, Current opinion in genetics & development.

[103]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[104]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 1981, Methods in enzymology.

[105]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[106]  J. Woodgett,et al.  Glycogen Synthase Kinase 3: A Kinase for All Pathways? , 2017, Current topics in developmental biology.

[107]  Dong-Wan Kim,et al.  In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. , 2015, Anticancer research.

[108]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[109]  G. Mills,et al.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. , 2008, Cancer research.

[110]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.